Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical trial
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf064 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Juliane Gust und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasm Recurrence, Local, Central Nervous System Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Alex's Lemonade Stand Foundation for Childhood Cancer, NCATS NIH HHS, St. Baldrick's Stand Up To Cancer Dream Team Translational Cancer Research.
Abstract (Originalsprache)
Background
Relapsed/refractory pediatric central nervous system (CNS) tumors have a poor prognosis. Epidermal growth factor receptor (EGFR) is commonly overexpressed, but EGFRvIII mutations are uncommon. To target these tumors, we used chimeric antigen receptor (CAR) T cells with a binder based on mAb806 which recognizes ectopically expressed wild-type EGFR and EGFRvIII.
Methods
In this open-label phase 1 clinical trial, patients aged 1–26 years with EGFR + CNS tumors received weekly infusions of 1–2.5 × 107 CAR T cells into the tumor resection bed or the lateral ventricle via an implanted catheter. No lymphodepletion was used.
Results
Eleven patients were enrolled. Four (3 with high-grade glioma, 1 with atypical teratoid rhabdoid tumor) were treated and received 5–10 CAR T cell infusions without dose-limiting toxicities. The trial closed prior to reaching planned dose regimens. All treatment-related adverse events were no higher than CTCAE grade 2. The most common were headache and nausea. One patient had a grade 1 seizure, and 3 had new sensory changes, weakness and/or urinary changes (grades 1–2) that were possibly related to CAR T cell infusion. A total of 3 of the 4 treated patients had progressive disease. One patient with spinal cord diffuse midline glioma had progressive peritumoral edema that could not be conclusively attributed to either progression or pseudoprogression and was, therefore, defined as stable disease, followed by a complete response to subsequent chemotherapy.
Conclusions
Intracranially infused EGFR806-CAR T cells were tolerable at tested doses, with the best response of stable disease. EGFR is a potentially useful target for cellular therapy against pediatric brain tumors, particularly high-grade gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
- Division of Pediatric Neurology, Department of Neurology, University of Washington, Seattle, Washington, USA.
- Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
- Department of Laboratory Medicine & Pathology, Seattle Children's/University of Washington, Seattle, Washington, USA.
- Clinical Research Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington, USA.
ORCID-Profile: Juliane Gust, Bonnie L Cole, Erin E Crotty
Förderung
- Alex's Lemonade Stand Foundation for Childhood Cancer
- NCATS NIH HHS
- St. Baldrick's Stand Up To Cancer Dream Team Translational Cancer Research
- Cancer is a division of the Entertainment Industry Foundation
- American Association for Cancer Research
- Alex’s Lemonade Stand Foundation for Childhood Cancer
- National Center for Advancing Translational Sciences
- St. Baldrick’s Stand Up To Cancer Dream Team Translational Cancer Research
Zitieren
APA
Gust, J., Cole, B. L., Ronsley, R., Wilson, A. L., Seidel, K., Wendler, J., Pattabhi, S., Brown, C., Rawlings-Rhea, S. D., Shtanukhina, N., Browd, S. R., Hauptman, J. S., Lee, A., Ojemann, J. G., Crotty, E. E., Leary, S. E. S., Perez, F. A., Wright, J. N., Albert, C. M., …, & Park, J. R. (2025). Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical trial. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf064
Vancouver
Gust J, Cole BL, Ronsley R, Wilson AL, Seidel K, Wendler J, et al. Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical trial. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf064
BibTeX
@article{Gust2025,
author = {Gust, Juliane and Cole, Bonnie L and Ronsley, Rebecca and Wilson, Ashley L and Seidel, Kristy and Wendler, Jason and Pattabhi, Sowmya and Brown, Christopher and Rawlings-Rhea, Stephanie D and Shtanukhina, Nadezhda and Browd, Samuel R and Hauptman, Jason S and Lee, Amy and Ojemann, Jeffrey G and Crotty, Erin E and Leary, Sarah E S and Perez, Francisco A and Wright, Jason N and Albert, Catherine M and Pinto, Navin and Gardner, Rebecca A and Vitanza, Nicholas A and Jensen, Michael C and Park, Julie R},
title = {Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical trial},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf064}
}
EUVIMED